November 06, 2024 02:57 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Union Minister HD Kumaraswamy booked for threatening cop probing into mining case | Supreme Court upholds validity of Uttar Pradesh Madrasa Education Act | Not all private properties are community resources that govt can take over: Supreme Court | Pakistan's Lahore has become world's most polluted city with an AQI of 1900 on Sunday | Indian Army 'successfully completes' patrolling to a key point in Ladakh's Depsang region
Biocon Q2FY21 revenue at Rs 1,760 cr, up 10 pc
Biocon
Image: Pixabay

Biocon Q2FY21 revenue at Rs 1,760 cr, up 10 pc

| @indiablooms | 23 Oct 2020, 05:12 pm

Bengaluru/UNI: Biocon Ltd, an innovation-led global biopharmaceuticals company on Friday announced its consolidated financial results for the fiscal second quarter ended September 30, 2020.

Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, “Consolidated revenue for Q2FY21 increased 10 per cent to Rs 1,760 Crore driven by 11 pc growth in Biosimilars, 12 pc in Research Services and 8 pc in Generics, businesses. EBITDA for the quarter stood at Rs 407 Crore and Net Profit(before exceptional item & discontinuing operations)was at Rs 174 Crore. Our profitability was impacted on account of higher R&D expenses, staff costs, other expenses and forex losses. However, our Core EBITDA margins stood at a healthy 32 pc, indicating sound operational performance.”

“Our Insulin Glargine, Semglee, was commercialized in the US by our partner Mylan, during the quarter, thus heralding our entry into the US Insulins market. With this launch, we have expanded our portfolio of Biosimilars and occupy a position of impactful influence in the Biosimilars segment.”

“As a part of our commitment to address the novel coronavirus pandemic in India, the Biocon Group is working on a comprehensive portfolio of products for treating mild to severely ill COVID-19 patients. We have introduced ARAFLU® (Favipiravir) in addition to Cytosorb and ALZUMAB-L, andSyngene has started manufacturing Remdesivir under a voluntary licensing agreement with Gilead,” she added. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.